GeneXpert rollout in three high-burden tuberculosis countries in Africa: A review of pulmonary tuberculosis diagnosis and outcomes from 2001 to 2019.
Africa
GeneXpert
Xpert MTB/RIF
interrupted time series
tuberculosis
Journal
African journal of laboratory medicine
ISSN: 2225-2002
Titre abrégé: Afr J Lab Med
Pays: South Africa
ID NLM: 101603205
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
24
05
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
The rollout of GeneXpert aimed at increasing early diagnosis of tuberculosis to improve treatment outcomes and global tuberculosis targets. This study evaluated trends in tuberculosis diagnosis and outcomes pre- and post-introduction of GeneXpert in three African countries - the Democratic Republic of the Congo (DRC), Nigeria and South Africa. Data from 2001 to 2019 were extracted from the World Health Organization's data repository. Descriptive analysis, paired Estimated tuberculosis incidence decreased from 327/100 000 to 324/100 000 in the DRC, and from 1220/100 000 to 988/100 000 in South Africa. Incidence remained at 219/100 000 in Nigeria. The tuberculosis case notification rate did not change significantly. Increases in the new case treatment success rates were statistically significant (DRC: Improvements in tuberculosis treatment outcomes were achieved, but little progress has been made in new case notification due to varied implementation and scale-up of GeneXpert across the three countries. Implementation barriers need to be addressed to achieve the required tuberculosis targets.
Sections du résumé
Background
UNASSIGNED
The rollout of GeneXpert aimed at increasing early diagnosis of tuberculosis to improve treatment outcomes and global tuberculosis targets.
Objective
UNASSIGNED
This study evaluated trends in tuberculosis diagnosis and outcomes pre- and post-introduction of GeneXpert in three African countries - the Democratic Republic of the Congo (DRC), Nigeria and South Africa.
Methods
UNASSIGNED
Data from 2001 to 2019 were extracted from the World Health Organization's data repository. Descriptive analysis, paired
Results
UNASSIGNED
Estimated tuberculosis incidence decreased from 327/100 000 to 324/100 000 in the DRC, and from 1220/100 000 to 988/100 000 in South Africa. Incidence remained at 219/100 000 in Nigeria. The tuberculosis case notification rate did not change significantly. Increases in the new case treatment success rates were statistically significant (DRC:
Conclusion
UNASSIGNED
Improvements in tuberculosis treatment outcomes were achieved, but little progress has been made in new case notification due to varied implementation and scale-up of GeneXpert across the three countries. Implementation barriers need to be addressed to achieve the required tuberculosis targets.
Identifiants
pubmed: 36091352
doi: 10.4102/ajlm.v11i1.1811
pii: AJLM-11-1811
pmc: PMC9453189
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1811Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):7-10
pubmed: 19145221
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
PLoS One. 2019 Sep 18;14(9):e0222421
pubmed: 31532797
Clin Infect Dis. 2010 May 15;50 Suppl 3:S245-54
pubmed: 20397955
BMC Health Serv Res. 2018 Dec 17;18(1):973
pubmed: 30558670
S Afr Med J. 2017 Nov 27;107(12):1078-1081
pubmed: 29262960
Microbiol Spectr. 2017 Jan;5(1):
pubmed: 28155817
PLoS One. 2017 Sep 7;12(9):e0184270
pubmed: 28880875
Sci Rep. 2019 Jul 24;9(1):10724
pubmed: 31341191
Niger Med J. 2019 Jan-Feb;60(1):33-39
pubmed: 31413433
Ann Glob Health. 2020 Feb 12;86(1):15
pubmed: 32090022
PLoS One. 2012;7(5):e36966
pubmed: 22693561
J Appl Microbiol. 2006 May;100(5):1011-6
pubmed: 16630001
Infect Dis Poverty. 2021 May 10;10(1):67
pubmed: 33971979
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860268
Clin Infect Dis. 2019 Sep 27;69(8):1278-1287
pubmed: 30759187
Gates Open Res. 2018 Jul 25;2:35
pubmed: 30234198
BMC Infect Dis. 2020 Jul 25;20(1):543
pubmed: 32711457
BMC Infect Dis. 2019 Jun 20;19(1):542
pubmed: 31221109
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
Lancet Glob Health. 2019 Feb;7(2):e161-e162
pubmed: 30683224
Am J Trop Med Hyg. 2018 Dec;99(6):1407-1414
pubmed: 30277200
Cochrane Database Syst Rev. 2021 May 6;5:CD012972
pubmed: 34097769
Eur Respir J. 2016 Aug;48(2):516-25
pubmed: 27418550
BMC Infect Dis. 2014 Jan 02;14:2
pubmed: 24383553
PLoS One. 2018 Jan 25;13(1):e0190258
pubmed: 29370162
Trans R Soc Trop Med Hyg. 2020 Sep 1;114(9):690-692
pubmed: 32300811